ISRCTN46471047CompletedNot Applicable
A multicentre, randomised, controlled, double-blind study, evaluating the efficacy and safety of anakinra in chondrocalcinosis (Étude multicentrique randomisée contrôlée en double-aveugle contre placebo, évaluant l?efficacité et la sécurité de l?anakinra dans la crise de chondrocalcinose articulaire)
niversity Hospital Centre and University of Lausanne (CHUV) (Switzerland)-Service of Rheumatology0 sites75 target enrollmentStarted: March 18, 2011Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 75
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Informed consent
- •2. Male or female from 18-99 years of age
- •3. Diagnosis of acute calcium pyrophosphate arthritis based on symptoms of acute arthritis and presence of crystals of chronic calcium pyrophosphate dihydrate (CPPD) in the synovial liquid at screening or from a prior analysis
- •4. The start of the acute arthritis should be less than 5 days from inclusion in the study
Exclusion Criteria
- •1. Corticotherapy orally with dose equivalent of prednisone > 10mg during the 24 h preceding inclusion
- •2. Corticotherapy intramuscular (im) or intravenous (iv) during the 72h preceding inclusion, no matter the dose
- •3. Corticotherapy intra-articularly during 7 days preceding inclusion
- •4. Chronic oral corticotherapy of > 10mg daily
- •5. Uncontrolled respiratory or cardiac failure
- •6. Other causes of acute arthritis
- •7. Active gastric or duodenal ulceration
- •8. Untreated and active malignancy
- •9. Known intolerance or allergy to the study medications
- •10. Active and untreated infection assessed by investigator as a contraindication to study medications
- •11. Other medical problems that are judged prejudicial to the inclusion of the patient in the study by the investigator
- •12. Pregancy or active breast feeding
Investigators
Similar Trials
Active, not recruiting
Phase 1
A multicenter, randomised, controlled, double-blind study to evaluate efficacy and safety of a perennial sublingual specific immunotherapy with a solution of grass pollen allergen extract in children with clinically relevant grass pollen sensitivity in comparison to a symptomatic standard treatment with add on placeboIgE-mediated allergic disease manifested as symptoms of allergic rhinitis/rhinoconjunctivitis with or without allergic bronchial asthma (GINA I and II), triggered by grass pollen allergens.MedDRA version: 9.1Level: LLTClassification code 10036019Term: Pollen allergyEUCTR2006-005911-82-PLAllergopharma Joachim Ganzer KG230
Recruiting
Not Applicable
A Multi-center, randomized controlled, double-blind, prospective, investigator trials to the safety and effectiveness of upper extremity function in patients with sub-acute and chronic stroke using optimized transcranial direct current stimulation (tDCS)Diseases of the circulatory systemKCT0006495The Catholic University of Korea, St. Vincent's Hospital42
Recruiting
Not Applicable
study to the safety and effectiveness of recovery of consciousness in patients with Prolonged disorders using optimized transcranial direct current stimulation (tDCS)Mental and behavioural disordersKCT0007157EUROPHET24
Active, not recruiting
Phase 1
A study to evaluate the effectiveness and safety of study drug (PeproStat) to stop bleeding during surgery.To achieve haemostasis when bleeding cannot be controlled by conventional methods alone, such as manual pressure, cauterization, or suturesor are inappropriate.MedDRA version: 20.0Level: LLTClassification code 10053001Term: Surgical haemostasisSystem Organ Class: 100000004865EUCTR2016-003661-26-HRHaemostatix Ltd300
Active, not recruiting
Phase 1
A study to evaluate the effectiveness and safety of study drug (PeproStat) to stop bleeding during surgery.To achieve haemostasis when bleeding cannot be controlled by conventional methods alone, such as manual pressure, cauterization, or suturesor are inappropriate.MedDRA version: 19.0 Level: LLT Classification code 10053001 Term: Surgical haemostasis System Organ Class: 100000004865EUCTR2016-003661-26-GBHaemostatix Ltd214